Healthcare Industry News: Valeant
News Release - September 12, 2008
Valeant Pharmaceuticals Completes Sale of Certain European Operations to Meda AB
ALISO VIEJO, Calif.--(HSMN NewsFeed)--Valeant Pharmaceuticals International (NYSE:VRX ) announced today that it has completed its sale of certain business operations located in Western Europe, Eastern Europe, and certain export markets to Meda AB, pursuant to the Acquisition Agreement entered into by Meda and Valeant on August 4, 2008. Valeant received approximately US$425 million in cash from Meda at closing, which is subject to certain closing adjustments.Goldman, Sachs & Co. served as financial advisor to Valeant and Skadden, Arps, Slate, Meagher & Flom LLP provided legal advice.
About Valeant
Valeant Pharmaceuticals International (NYSE:VRX ) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.Valeant.com.
Source: Valeant Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!